DEPO-PROVERA

LOE Approaching

medroxyprogesterone acetate

NDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
6

Mechanism of Action

Suspension, USP inhibits the secretion of gonadotropins which primarily prevents follicular maturation and ovulation and causes thickening of cervical mucus. These actions contribute to its contraceptive effect.

Clinical Trials (5)

NCT04682353Phase 1Completed

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

Started Dec 2020
60 enrolled
Contraception
NCT02817464Phase 1Completed

Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle

Started Oct 2016
12 enrolled
PregnancyContraception
NCT00770887N/ACompleted

Self Administration of Subcutaneous Depot Medroxyprogesterone Acetate

Started May 2010
50 enrolled
Fertility
NCT00437658Phase 2Completed

Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis

Started Dec 2006
252 enrolled
Endometriosis
NCT00830414Phase 1Completed

Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women

Started Apr 2002
124 enrolled
Healthy